KR20100017971A - 에어로졸화 항응고제의 사용을 통해 폐 조직에서 피브린 응고를 예방하는 방법 - Google Patents

에어로졸화 항응고제의 사용을 통해 폐 조직에서 피브린 응고를 예방하는 방법 Download PDF

Info

Publication number
KR20100017971A
KR20100017971A KR1020097027466A KR20097027466A KR20100017971A KR 20100017971 A KR20100017971 A KR 20100017971A KR 1020097027466 A KR1020097027466 A KR 1020097027466A KR 20097027466 A KR20097027466 A KR 20097027466A KR 20100017971 A KR20100017971 A KR 20100017971A
Authority
KR
South Korea
Prior art keywords
heparin
drug
atiii
lung injury
antithrombin iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020097027466A
Other languages
English (en)
Korean (ko)
Inventor
페렌렐이 엔크바아타르
가즈노리 무라카미
다니엘 엘. 트래버
Original Assignee
지티씨바이오쎄라퓨틱스,인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 지티씨바이오쎄라퓨틱스,인크. filed Critical 지티씨바이오쎄라퓨틱스,인크.
Publication of KR20100017971A publication Critical patent/KR20100017971A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020097027466A 2004-02-20 2005-02-15 에어로졸화 항응고제의 사용을 통해 폐 조직에서 피브린 응고를 예방하는 방법 Abandoned KR20100017971A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US54623604P 2004-02-20 2004-02-20
US60/546,236 2004-02-20
US11/057,522 US20050192226A1 (en) 2004-02-20 2005-02-14 Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
US11/057,522 2005-02-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020067019275A Division KR20060130661A (ko) 2004-02-20 2005-02-15 에어로졸화 항응고제의 사용을 통해 페 조직에서 피브린응고를 예방하는 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020117015353A Division KR20110084555A (ko) 2004-02-20 2005-02-15 에어로졸화 항응고제의 사용을 통해 폐 조직에서 피브린 응고를 예방하는 방법

Publications (1)

Publication Number Publication Date
KR20100017971A true KR20100017971A (ko) 2010-02-16

Family

ID=34889863

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020097027466A Abandoned KR20100017971A (ko) 2004-02-20 2005-02-15 에어로졸화 항응고제의 사용을 통해 폐 조직에서 피브린 응고를 예방하는 방법
KR1020117015353A Ceased KR20110084555A (ko) 2004-02-20 2005-02-15 에어로졸화 항응고제의 사용을 통해 폐 조직에서 피브린 응고를 예방하는 방법
KR1020067019275A Ceased KR20060130661A (ko) 2004-02-20 2005-02-15 에어로졸화 항응고제의 사용을 통해 페 조직에서 피브린응고를 예방하는 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020117015353A Ceased KR20110084555A (ko) 2004-02-20 2005-02-15 에어로졸화 항응고제의 사용을 통해 폐 조직에서 피브린 응고를 예방하는 방법
KR1020067019275A Ceased KR20060130661A (ko) 2004-02-20 2005-02-15 에어로졸화 항응고제의 사용을 통해 페 조직에서 피브린응고를 예방하는 방법

Country Status (10)

Country Link
US (2) US20050192226A1 (https=)
EP (2) EP1725244B1 (https=)
JP (2) JP2007533657A (https=)
KR (3) KR20100017971A (https=)
AT (1) ATE493135T1 (https=)
AU (1) AU2005216044B2 (https=)
CA (1) CA2557411A1 (https=)
DE (1) DE602005025610D1 (https=)
IL (1) IL177588A0 (https=)
WO (1) WO2005081816A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100117148A (ko) * 2002-04-01 2010-11-02 지티씨바이오쎄라퓨틱스,인크. 폐 질환의 치료 방법
US20050169908A1 (en) * 2004-01-23 2005-08-04 Kazunori Murakami Use of aerosolized antithrombin to treat acute lung injury
US20050192226A1 (en) * 2004-02-20 2005-09-01 Perenlei Enkhbaatar Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
US20050245444A1 (en) * 2004-04-30 2005-11-03 Yann Echelard Method of using recombinant human antithrombin for neurocognitive disorders
US20060121004A1 (en) * 2004-12-07 2006-06-08 Yann Echelard Methods of reducing the incidence of rejection in tissue transplantation through the use of recombinant human antithrombin
KR20140093603A (ko) 2010-12-30 2014-07-28 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 병원체 불활성화제로서의 글리콜
EP2928480B1 (en) 2012-12-05 2019-09-25 National Jewish Health Treatment for airway cast obstruction
US10034921B2 (en) 2013-02-13 2018-07-31 Laboratoire Français Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
EP3594231A1 (en) 2013-02-13 2020-01-15 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
MX384222B (es) 2013-07-05 2025-03-14 Lab Francais Du Fractionnement Matriz de cromatografia de afinidad.
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
WO2021201950A1 (en) * 2020-04-04 2021-10-07 The Board Of Regents Of The University Of Texas System Method for reducing the occurrence of thrombosis or thromboembolism

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127347A (en) * 1994-01-12 2000-10-03 Univ Michigan Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
US6355626B1 (en) * 1994-05-13 2002-03-12 The Trustees Of The University Of Pennsylvania Antithrombin agents in treatment of asthma
US5843705A (en) * 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
US7045585B2 (en) * 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
US6063593A (en) * 1996-11-12 2000-05-16 University Of Southern California University Park Campus TGFβ1 responsive bone marrow derived cells to express a recombinant protein
US6124257A (en) * 1997-08-28 2000-09-26 Lezdey; John Method of treatment
AU2002224408B2 (en) * 2000-10-18 2007-08-23 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
DE10132307A1 (de) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
KR20100117148A (ko) * 2002-04-01 2010-11-02 지티씨바이오쎄라퓨틱스,인크. 폐 질환의 치료 방법
US20050169908A1 (en) * 2004-01-23 2005-08-04 Kazunori Murakami Use of aerosolized antithrombin to treat acute lung injury
US20050192226A1 (en) * 2004-02-20 2005-09-01 Perenlei Enkhbaatar Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants

Also Published As

Publication number Publication date
EP1725244A4 (en) 2009-08-12
EP2322189A3 (en) 2011-07-27
EP1725244A2 (en) 2006-11-29
IL177588A0 (en) 2008-03-20
AU2005216044B2 (en) 2011-07-14
EP1725244B1 (en) 2010-12-29
AU2005216044A1 (en) 2005-09-09
WO2005081816A3 (en) 2007-02-01
EP2322189A2 (en) 2011-05-18
KR20110084555A (ko) 2011-07-25
CA2557411A1 (en) 2005-09-09
JP2011162555A (ja) 2011-08-25
JP2007533657A (ja) 2007-11-22
DE602005025610D1 (de) 2011-02-10
US20110070167A1 (en) 2011-03-24
KR20060130661A (ko) 2006-12-19
US20050192226A1 (en) 2005-09-01
WO2005081816A2 (en) 2005-09-09
ATE493135T1 (de) 2011-01-15

Similar Documents

Publication Publication Date Title
US20110070167A1 (en) Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
KR20060127992A (ko) 급성 폐 손상을 치료하기 위한 에어로졸화 항트롬빈의 용도
SG185972A1 (en) Compositions and methods for treatment of microbial disorders
JP2015502370A (ja) 炎症性疾患の治療のための組換えヒトα１−抗トリプシン
KR20090114341A (ko) Ｆｇｆ2를 유효성분으로 포함하는 천식 및 만성폐쇄성 폐질환 예방 또는 치료제
US20060121004A1 (en) Methods of reducing the incidence of rejection in tissue transplantation through the use of recombinant human antithrombin
EP1390407B1 (en) The lectin-like domain of thrombomodulin and its therapeutic use
KR102772403B1 (ko) 알파-1 안티 트립신 결핍증 z 타입 돌연변이의 교정을 위한 프라임에디팅 가이드 rna를 포함하는 프라임에딩팅용 조성물
Turner Alpha-1 antitrypsin deficiency: new developments in augmentation and other therapies
JPH10508756A (ja) 造血タンパク質を用いて赤血球形成を刺激する方法
US20050245444A1 (en) Method of using recombinant human antithrombin for neurocognitive disorders
AU2011202575A1 (en) Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
CN1946419A (zh) 使用气溶胶化抗凝血酶治疗急性肺损伤
AU2002312938B2 (en) The lectin-like domain of thrombomodulin and its therapeutic use
EP2390261A2 (en) Modified human thrombopoietin polypeptide fragment and manufacturing method thereof
CN116920093A (zh) Mmp9抑制剂及mmp9缺陷型树突状细胞及其抗炎作用
WO2005112968A2 (en) Method of using recombinant human antithrombin for neurocognitive disorders
AU2002312938A1 (en) The lectin-like domain of thrombomodulin and its therapeutic use

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20091230

Application number text: 1020067019275

Filing date: 20060919

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20100212

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20100512

Patent event code: PE09021S01D

AMND Amendment
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20110322

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20110531

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20100512

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
AMND Amendment
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20110701

Application number text: 1020067019275

Filing date: 20060919

PJ0201 Trial against decision of rejection

Patent event date: 20110701

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20110531

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20121026

Appeal identifier: 2011101004476

Request date: 20110701

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20110701

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20110701

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20101112

Patent event code: PB09011R02I

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial
J301 Trial decision

Free format text: TRIAL NUMBER: 2011101004476; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20110701

Effective date: 20121026

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20121026

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20110701

Decision date: 20121026

Appeal identifier: 2011101004476

PS0901 Examination by remand of revocation
S901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

Patent event date: 20121123

Patent event code: PS07012S01D

Comment text: Decision to Grant Registration

Patent event date: 20121026

Patent event code: PS07011S01I

Comment text: Notice of Trial Decision (Remand of Revocation)

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee